A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants

This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.

Inclusion Criteria: * Sign the informed consent form and be able to complete the research as required. * Age and weight meet the requirements. * During the screening, the results of physical examination, vital signs, laboratory tests, electrocardiogram, etc. are normal or have no clinical significance(healthy individuals). * Take effective contraceptive measures as required. * During the screening, HBsAg, HBV DNA, ALT, and HBeAg meet certain indicators (CHB participants). Exclusion Criteria: * Have a serious systemic disease or a history of malignant tumor. * Have other liver diseases besides chronic HBV infection, or have liver dysfunction, significant liver fibrosis/ cirrhosis, history of liver cell carcinoma or suspected cases. * Have autoimmune diseases or diseases with a risk of immune activation. * Have a questionable allergy to the test drugs and their components, or have an allergic constitution. * Participate in other clinical trials or receive investigational drug treatment within the specified time before screening, and have received related drug * Have received solid organ transplantation or hematopoietic stem cell transplantation before screening. * Have acute infection, major trauma or major surgery with clinical significance that has not fully recovered within the specified time before screening, or have a surgical plan during the study. * Have abnormal laboratory tests, vital signs or electrocardiogram results during screening and have clinical significance as judged by the researcher. * Have positive screening for related infectious diseases. * Have a history of drug abuse or alcoholism; or have a large amount of smoking before screening and cannot stop during the study. * Have consumed caffeine, xanthine-containing foods or beverages, or engaged in intense exercise within the specified time before administration, or have been unable to stop during the study. * Have positive urine drug screening or alcohol breath test during screening; have donated blood or lost a large amount of blood before screening, received blood transfusion, or have a blood donation plan during the study. * Have a positive pregnancy test during screening. * Abnormal skin at the injection site. * Have a history of fainting or hemisomnia, difficulty in blood collection, or inability to tolerate venipuncture blood collection. * The researcher considers that there are other factors that make one unsuitable to participate in this trial.